CGRP mAb Subcutaneous denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a Quantity-Limits Denial for Your CGRP Monoclonal Antibody

A quantity-limits denial from Cigna means the prescription as written requests a supply — number of injections, prefilled syringes, or autoinjectors per fill or per period — that exceeds the maximum quantity Cigna's formulary allows without additional authorization. For subcutaneous CGRP monoclonal antibodies, this most commonly arises when the prescriber writes for a quantity consistent with the FDA-labeled dosing schedule but Cigna's plan-level limit is set lower, or when a loading-dose regimen is prescribed that temporarily requires a higher quantity in the first fill.

## Why This Denial Is Appealable

If the prescribed quantity exactly matches the FDA-approved dosing schedule in the prescribing label, the denial is directly challengeable on the grounds that the plan's limit conflicts with the standard of care. If a loading dose creates a higher first-fill quantity, the prescriber can document the clinical rationale. Quantity-limit appeals succeed most often when the prescriber provides a letter confirming the quantity is consistent with the labeled regimen and medically necessary.

## Your Federal Appeal Rights

• ACA §2719 external review is available after a final internal denial; the window is generally approximately four months.
• ERISA §503 governs self-funded plans and requires a full-and-fair review with timely decisions.
• Expedited review is available if restricting the quantity causes imminent clinical harm.
• Many states have additional quantity-limit appeal protections for fully insured plans.

## Documentation to Gather

• FDA prescribing label: from DailyMed, showing the approved dosing regimen (including any loading-dose instructions); the prescribed quantity should match this regimen exactly.
• Prescriber medical-necessity letter: confirms that the quantity prescribed aligns with FDA-approved dosing, explains any loading-dose rationale if applicable, and states that a reduced quantity would result in subtherapeutic dosing.
• Pharmacy dispensing consultation note (if applicable): clinical pharmacist documentation confirming the quantity is consistent with the labeled regimen.
• Cigna's quantity-limit policy: download the current limit and the exception criteria from cigna.com; your letter should cite the exception criteria your case meets.

## Criteria-Mapping Structure

| Cigna Quantity-Limit Criterion | Supporting Evidence | |---|---| | Quantity exceeds standard dosing | FDA label showing approved regimen; prescriber confirmation quantity matches label | | Loading dose increases first-fill quantity | Prescriber letter with clinical rationale citing label | | Medical necessity of requested quantity | Prescriber attestation that reduced quantity = subtherapeutic dosing |

Verify the exact quantity limits and exception pathway in Cigna's current published formulary and coverage policy and cross-check against the FDA-approved prescribing label before filing. Both can change annually during plan renewal cycles.